ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2425

Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)

Jens Klotsche1, Martina Niewerth2, Johannes Peter Haas3, Angela Zink4, Gerd Horneff5 and Kirsten Minden6, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, 4Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: drug treatment, juvenile idiopathic arthritis (JIA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients with JIA are rare. The aim of the study was to investigate the safety of tocilizumab in routine care in young adults with JIA.

Methods: Patients with JIA were enrolled in the national JIA biologic register BiKeR and were prospectively followed into adulthood in the follow-up register JuMBO.  All adverse events (AE) were recorded by physicians over the observation period and were categorized on the basis of MedDRA. An event was attributed to tocilizumab when the treatment was either ongoing or terminated in less than 3 months prior to the event. Rates of AE and serious AE (SAE) were calculated per 100 years of tocilizumab exposure (EY).

Results: A total of 929 JIA patients were included in the JuMBO register by the end of January 2015. The tolerability of tocilizumab could be studied in 87 patients (143 EY) who were ever exposed to tocilizumab (14 sJIA, 63 pJIA). Tocilicumab was the first-line biologic disease modifying antirheumatic drugs (DMARD) in 4 (5%) patients, the other 83 patients were treated with tocilizumab after treatment failures with other biologics (second-line bDMARD in 26%, third-line in 47%). In the majority of cases (78%) tocilicumab was first prescribed in young adulthood. At the last available JuMBO visit, 63 patients (8 sJIA, 49 pJIA) were on current treatment with tocilizumab. At treatment start with tocilizumab, patients had a mean disease duration of 13 years, a mean age of 23 years and had been treated in mean by 4.5 other DMARDs before tocilizumab. A total of 81 AE (56.6 events/100 EY) were recorded and 19 (13.3 events/100 EY) AE were rated as serious. Among the SAE, 10 surgical and medical procedures (7.0 events/ 100EY), 4 infections (2.8 events/ 100EY, herpes zoster, genital herpes, norovirus infection, pneumonia) and 2 gastrointestinal disorders (1.4 events/ 100EY) were reported.

Conclusion: Tocilizumab is often started at first time in JIA patients in young adulthood and after treatment failure with other biologic DMARDs. Thus, the JuMBO register supplements the findings about drug safety from the BiKeR register. The obtained safety data are similar to those of tocilizumab in children and of other biologics used in young adults with JIA. However, the number of observed years of drug exposure is still very limited.


Disclosure: J. Klotsche, None; M. Niewerth, None; J. P. Haas, None; A. Zink, None; G. Horneff, None; K. Minden, None.

To cite this abstract in AMA style:

Klotsche J, Niewerth M, Haas JP, Zink A, Horneff G, Minden K. Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/safety-of-tocilizumab-in-young-adults-with-juvenile-idiopathic-arthritis-jia/. Accessed February 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-tocilizumab-in-young-adults-with-juvenile-idiopathic-arthritis-jia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.